Filtered By:
Drug: Temodar

This page shows you your search results in order of relevance.

Order by Relevance | Date

Total 98 results found since Jan 2013.

Combination of B7H6-siRNA and temozolomide synergistically reduces stemness and migration properties of glioblastoma cancer cells
This study aimed to understand the potential role and molecular mechanism of the combination therapy of B7H6-siRNA and temozolomide in glioblastoma cancer. U87 cells were treated with B7H6-siRNA and temozolomide, separately and in combination. Cell viability, stemness, cell migration, and apoptosis were measured. The results of this work presented the synergistic effect of B7H6-siRNA and temozolomide in inhibiting the cancerous features of the U87 cell line. Down-regulating B7H6-siRNA expression inhibited the cell viability of U87 glioblastoma cancer cells and increased their sensitivity to temozolomide. In addition, a not...
Source: Experimental Cell Research - May 29, 2023 Category: Cytology Authors: Nadia Allahyarzadeh Khiabani Mohammad Amin Doustvandi Fateme Mohammadnejad Elnaz Salmani Hassan Kohal Neda Boushehri Mahdi Jafarlou Behzad Baradaran Source Type: research

Combination Therapy with AKT3 and PI3KCA siRNA Enhances the Antitumor Effect of Temozolomide and Carmustine in T98G Glioblastoma Multiforme Cells
Conclusion The siRNA-induced AKT3 and PI3KCA mRNA knockdown in combination with TMZ and BCNU inhibited proliferation and induced apoptosis and autophagy in T98G cells. Thus, knockdown of these genes in combination with TMZ and BCNU may offer a novel therapeutic strategy to more effectively control the growth of human GBM cells, but further studies are necessary to confirm a positive phenomenon for the treatment of GBM.
Source: BioDrugs - February 22, 2016 Category: Drugs & Pharmacology Source Type: research

Preclinical evaluation of an O(6)-methylguanine-DNA methyltransferase-siRNA/liposome complex administered by convection-enhanced delivery to rat and porcine brains.
In this study, we aim to evaluate the safety of MGMT-siRNA/cationic liposome complexes and determine whether the convection-enhanced delivery of these complexes is suitable for clinical use by undertaking preclinical testing in laboratory animals. No significant adverse events were observed in rats receiving infusions of MGMT-siRNA/cationic liposome complex directly into the brain with or without TMZ administration. A pig which received the complex administered by CED also showed no evidence of neurological dysfunction or histological abnormalities. However, the complex did not appear to achieve effective distribution by C...
Source: American Journal of Translational Research - November 14, 2014 Category: Research Tags: Am J Transl Res Source Type: research

siRNA targeting stathmin inhibits invasion and enhances chemotherapy sensitivity of stem cells derived from glioma cell lines.
Abstract Glioma is one of the most highly angiogenic tumors, and glioma stem cells (GSCs) are responsible for resistance to chemotherapy and radiotherapy, as well as recurrence after operation. Stathmin is substantial for mitosis and plays an important role in proliferation and migration of glioma-derived endothelial cells. However, the relationship between stathmin and GSCs is incompletely understood. Here we isolated GSCs from glioma cell lines U87MG and U251, and then used siRNA targeting stathmin for silencing. We showed that silencing of stathmin suppressed the proliferation, increased the apoptosis rate, and...
Source: Acta Biochimica et Biophysica Sinica - October 27, 2014 Category: Biochemistry Authors: Song Y, Mu L, Han X, Liu X, Fu S Tags: Acta Biochim Biophys Sin (Shanghai) Source Type: research

Kill two birds with one stone: Engineered exosome-mediated delivery of cholesterol modified YY1-siRNA enhances chemoradiotherapy sensitivity of glioblastoma
In this study, we utilize the engineering technology to generate T7 peptide-decorated exosome (T7-exo). T7 is a peptide specifically binding to the transferrin receptor. T7-exo shows excellent packaging and protection of cholesterol-modified Cy3-siYY1 while quickly releasing payloads in a cytoplasmic reductive environment. The engineered exosomes T7-siYY1-exo could deliver more effciently to GBM cells both in vitro and in vivo. Notably, in vitro experiments demonstrate that T7-siYY1-exo can enhance chemoradiotherapy sensitivity and reverse therapeutic resistance. Moreover, T7-siYY1-exo and TMZ/IR exert synergistic anti-GBM...
Source: Frontiers in Pharmacology - August 19, 2022 Category: Drugs & Pharmacology Source Type: research

The nanoprodrug of polytemozolomide combines with MGMT siRNA to enhance the effect of temozolomide in glioma
Drug Deliv. 2023 Dec;30(1):1-13. doi: 10.1080/10717544.2022.2152911.ABSTRACTTemozolomide (TMZ) is a conventional chemotherapeutic drug for glioma, however, its clinical application and efficacy is severely restricted by its drug resistance properties. O6-methylguanine-DNA methyltransferase (MGMT) is a DNA repair enzyme, which can repair the DNA damage caused by TMZ. A large number of clinical data show that reducing the expression of MGMT can enhance the chemotherapeutic efficacy of TMZ. Therefore, in order to improve the resistance of glioma to TMZ, an angiopep-2 (A2) modified nanoprodrug of polytemozolomide (P(TMZ)n) tha...
Source: Drug Delivery - December 29, 2022 Category: Drugs & Pharmacology Authors: Haoyue Xu Yongkang Zhang Linfeng Li Yanhong Ren Feng Qian Lansheng Wang Hongwei Ma Ankang Quan Hongmei Liu Rutong Yu Source Type: research

CD73 as a target to improve temozolomide chemotherapy effect in glioblastoma preclinical model
AbstractGlioblastoma is the most devastating primary brain tumor and effective therapies are not available. Treatment is based on surgery followed by radio and chemotherapy with temozolomide (TMZ), but TMZ increases patient survival only by 2  months. CD73, an enzyme responsible for adenosine production, emerges as a target for glioblastoma treatment. Indeed, adenosine causes tumor-promoting actions and CD73 inhibition increases sensitivity to TMZ in vitro. Here, a cationic nanoemulsion to nasal delivery of siRNA CD73 (NE-siRNA CD73) ai ming glioblastoma treatment was employed alone or in combination with TMZ. In vitro, t...
Source: Cancer Chemotherapy and Pharmacology - May 15, 2020 Category: Cancer & Oncology Source Type: research

Combination Treatment with Theranostic Nanoparticles for Glioblastoma Sensitization to TMZ
Conclusions While our results demonstrate that siRNA delivery by targeted nanoparticles resulted in modulating tumor response to chemotherapy in GBM, they also point to a significant contribution of CTX to tumor cell death.
Source: Molecular Imaging and Biology - September 26, 2014 Category: Molecular Biology Source Type: research

WNK1-OSR1 kinase-mediated phospho-activation of Na+-K+-2Cl- cotransporter facilitates glioma migration
Conclusion: Together, our data show a novel role for the WNK1/OSR1/NKCC1 pathway in basal and TMZ-induced glioma migration, and suggest that glioma treatment with TMZ might be improved by drugs that inhibit elements of the WNK1/OSR1/NKCC1 signaling pathway.
Source: Molecular Cancer - February 20, 2014 Category: Cancer & Oncology Authors: Wen ZhuGulnaz BegumKelli PointerPaul ClarkSung-Sen YangShih-Hua LinKristopher KahleJohn KuoDandan Sun Source Type: research

Quercetin sensitizes human glioblastoma cells to temozolomide in vitro via inhibition of Hsp27.
Conclusion:Combined treatment with TMZ and quercetin efficiently suppressed human glioblastoma cell survival in vitro. PMID: 24902789 [PubMed - in process]
Source: Acta Pharmacologica Sinica - June 1, 2014 Category: Drugs & Pharmacology Authors: Sang DP, Li RJ, Lan Q Tags: Acta Pharmacol Sin Source Type: research